Get started
Author

Saubia Fathima

Observed name: Fathima Saubia
Institution: Mayo Clinic
Observed institutions: Mayo Clinic, Rashid Hospital
ORCID: 0000-0002-9979-7923
Observed ORCID: 0000-0002-9979-7923
OpenAlex ID: A5089798132
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance
2025 · Ayalew Tefferi, Maymona Abdelmagid, et al. · American Journal of Hematology · 28
PDF
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia
2025 · Ayalew Tefferi, Saubia Fathima, et al. · Blood · 23
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases
2025 · Saubia Fathima, Maymona Abdelmagid, et al. · American Journal of Hematology · 13
PDF
PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis
2024 · Ayalew Tefferi, Saubia Fathima, et al. · American Journal of Hematology · 6
PDF
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026 · Luca Lanino, Anthony M. Hunter, et al. · Journal of Clinical Oncology · 5
Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
2025 · Saubia Fathima, Ali Alsugair, et al. · Blood Cancer Journal · 4
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients
2025 · Ali Alsugair, Estefania Gauto Mariotti, et al. · Blood Cancer Journal · 3
PDF
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes
2025 · Clifford M. Csizmar, Anuya Natu, et al. · Leukemia · 3
Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents
2026 · Saubia Fathima, Margaret Mei‐Kay Wong, et al. · American Journal of Hematology · 2
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
2026 · Saubia Fathima, Lior Rokach, et al. · Blood Cancer Journal · 2
PDF
Validation of BLAST and BLAST ‐Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo–Humanitas Collaborative Project Involving 1101 Patients
2025 · Saubia Fathima, Ali Alsugair, et al. · American Journal of Hematology · 2
PDF
Myeloproliferative Neoplasms‐Unclassifiable ( MPN ‐U): A Carefully Curated Series of 30 Mayo Clinic Patients
2025 · Rania M. Abdelaziz, Priyansh Faldu, et al. · American Journal of Hematology · 2
PDF
Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates
2025 · Sarah Dingli, Saubia Fathima, et al. · Blood Cancer Journal · 2
PDF
Sodium-glucose co-transporter-2 inhibitor treatmentassociated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
2025 · Ali Alsugair, Saubia Fathima, et al. · Haematologica · 2
PDF
Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors
2024 · Fnu Aperna, Ali K. Alsugair, et al. · Haematologica · 2
PDF
CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia
2026 · Saubia Fathima, Lior Rokach, et al. · Blood Cancer Journal · 1
PDF
One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol
2026 · Muhammad Yousuf, Saubia Fathima, et al. · Blood Cancer Journal · 1
PDF
SH2B3 (Lnk) Mutations in Myeloid Neoplasms: Morphologic Spectrum, Co‐Mutation Patterns, and Clinical Correlates
2025 · Ayalew Tefferi, Muhammad Yousuf, et al. · American Journal of Hematology · 1
PDF
A retrospective analysis of upfront treatment strategies in chronic myelomonocytic leukemia: impact on survival and response patterns
2025 · Muhammad Yousuf, Priyansh Faldu, et al. · Haematologica · 1
PDF
Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients.
2025 · Muhammad Yousuf, Ayalew Tefferi, et al. · Journal of Clinical Oncology · 1
Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform
2024 · Ayalew Tefferi, Saubia Fathima, et al. · Blood · 1
Role of Clinical, Laboratory, and Radiological Manifestations in Prognostication of COVID-19 in 804 Patients Admitted to Three Tertiary Care Centers in Dubai, United Arab Emirates
2022 · Mehdi Rommana, Khan Arshee, et al. · Journal of Infectious Diseases and Epidemiology · 1
PDF
Engraftment across major ABO blood group and rhesus E antigen incompatibility in the presence of persistent anti-E antibodies and late serologic findings coinciding with disease relapse
2026 · Saubia Fathima, Luz Y Sullivan, et al. · BMJ Case Reports
PDF
One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: Co-mutation patterns and prognostic correlates.
2026 · Muhammad Yousuf, Saubia Fathima, et al. · Journal of Clinical Oncology
Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients
2025 · Rania Abdelaziz, Priyansh Faldu, et al. · Blood
Works count: 36
Citation count: 106
H-index: 5
I10-index: 3
Year
Topic
Type